Articles tagged with: Kyprolis
This past Sunday was the second day of the American Society of Hematology’s (ASH) annual meeting, which was held in San Francisco.
As on the first day of the meeting, myeloma-related presentations once again took place during several sessions throughout the day.
A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.
While the education session was being held, a separate “scientific symposium” with two oral presentations took place in parallel. The session focused on a novel immunotherapeutic approach to treating cancer …
Saturday was the official first day of the 2014 American Society of Hematology (ASH) annual meeting. The day featured a wide range of interesting presentations about multiple myeloma.
Oral presentations about new treatments under development were given mid-day and were summarized in a Beacon ASH Daily Update published yesterday morning.
During Saturday evening, a poster session took place where important new research findings were summarized in posters displayed throughout two separate large conference halls.
The studies covered a variety of myeloma-related topics, ranging from new treatments being developed for myeloma, …
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in San Francisco.
Myeloma-related presentations were made during several sessions throughout the day.
The day started out with a session designed to better educate physicians about multiple myeloma and how to treat the disease.
Two sessions of oral presentations devoted solely to multiple myeloma ran simultaneously in the middle of the day. One of the sessions focused on the biology of the disease. The other one included presentations on new myeloma therapies for both newly diagnosed and …
Amgen has given a first glimpse of key results from its FOCUS Phase 3 clinical trial testing Kyprolis in relapsed and refractory multiple myeloma patients.
The company reported this past Wednesday that Kyprolis did not provide an overall survival advantage in the trial, which is being conducted outside the United States.
In addition, the company noted that patients treated with Kyprolis during the trial experienced more kidney-related side effects than patients who were not treated with the drug.
Up until recently, the primary significance of the FOCUS trial would have …
Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial comparing Kyprolis-Revlimid-dexamethasone to Revlimid-dexamethasone in patients with relapsed multiple myeloma.
Patients in the trial who received the Kyprolis-Revlimid-dexamethasone combination (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dexamethasone (Rd) (17.6 months).
There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. However, the difference is not yet statistically significant.
The results of the trial are important for two …